Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors

Johnson & Johnson (JNJ) underperformed the S&P 500 in the latest trading session and over the past month, with the stock down 1.42% versus the S&P 500's 13.42% gain. Upcoming earnings are expected to show a year-over-year EPS decline of 6.03%, although revenue is projected to increase by 1.42%. The company's forward P/E ratio of 14.45 is at a premium compared to its industry's average of 13.21, and it currently holds a Zacks Rank #3 (Hold).

Analysis

Johnson & Johnson (JNJ) has demonstrated recent underperformance, with its stock declining 0.44% in the latest trading session to $152.51 and falling 1.42% over the past month, significantly lagging the S&P 500's 13.42% gain and the Medical sector's 1.44% increase during the same period. The upcoming quarterly earnings report presents a mixed outlook: analysts project earnings per share (EPS) of $2.65, which would represent a 6.03% year-over-year decline, while revenue is anticipated to increase by 1.42% to $22.77 billion. In contrast, full-year Zacks Consensus Estimates are more positive, forecasting an EPS of $10.60 (+6.21% YoY) and revenue of $91.19 billion (+2.66% YoY). Despite a marginal 0.04% upward revision in the Zacks Consensus EPS estimate over the past month, JNJ currently holds a Zacks Rank #3 (Hold). From a valuation standpoint, JNJ trades at a Forward P/E ratio of 14.45, a premium to its industry's average of 13.21. Furthermore, its PEG ratio of 2.32 is substantially higher than the Large Cap Pharmaceuticals industry average of 1.21, indicating potential overvaluation relative to its anticipated earnings growth, even though its industry ranks favorably in the top 17% of all 250+ industries.

Key Decisions for Investors

• Investors should closely monitor Johnson & Johnson's upcoming earnings release for clarification on the drivers behind the projected quarterly EPS decline and the sustainability of the forecasted full-year growth, particularly in light of the stock's recent market underperformance.
• The company's current valuation, evidenced by a premium Forward P/E ratio and a significantly elevated PEG ratio compared to its industry peers, warrants careful assessment of whether JNJ's growth prospects adequately justify these metrics.
• Given the Zacks Rank #3 (Hold) and the mixed signals from short-term earnings expectations versus full-year forecasts and valuation, maintaining current positions while awaiting further clarity from the earnings report and observing any shifts in analyst estimates or valuation multiples may be a prudent strategy.